The COVID-19 pandemic and previous health emergencies have emphasised the critical need to enhance technologies that facilitate rapid responses in times of crisis. A key aspect of this preparedness is the development and accessibility of prototype vaccines, which are fundamental to pandemic readiness.
In response to this need, the European Vaccine Hub (EVH) has been inaugurated in Siena to improve Europe’s vaccine readiness and responsiveness during pandemics. This initiative consists of essential actions to expedite vaccine development to less than four months after identifying a pathogen’s genomic sequence.
The Hub will integrate nationally-funded vaccine research and development investments at the EU level, comprising a consortium of leading European organisations specialising in vaccine development and national pandemic preparedness programs. Each organisation will contribute extensive vaccine discovery, development, clinical trials, and manufacturing expertise.
“With the launch of the European Vaccine Hub, we take a significant step forward in ensuring that Europe is prepared to respond swiftly and effectively to future pandemics. This initiative embodies the spirit of European collaboration, uniting our finest minds and resources across borders to protect the health of our citizens and strengthen our global leadership in vaccine development. Europe is investing in a resilient, sustainable future where we can rapidly deliver life-saving vaccines to those who need them most,” Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, said.
The EVH project is supported by the European Commission’s Health Emergency Preparedness and Response Authority (HERA) through the EU4Health programme, with a funding allocation of up to €102 million. The Hub aims to transform vaccine development through its agile, decentralised structure, promoting European collaborative research. It will also ensure sustainability and continued operation beyond the initial funding period, enhancing Europe’s capacity to safeguard its citizens and fortify its economy against global health threats.
The EVH will concentrate on several key actions, including accelerating vaccine development to less than four months from identifying a pathogen’s genomic sequence, initiating a prototype vaccine strategy utilising advanced platform technologies, and leveraging resources from both public and private sectors. Furthermore, the EVH will lead preclinical studies, Phase I/II trials, and Controlled Human Infection Model (CHIM) trials. Industry partnerships will also facilitate seamless access to vaccine production facilities, clinical trial sites, analytical laboratories, technology transfers, and expanded production capabilities.
